Drugs / Verelan® PM Extended-Release Capsules, 300 mg
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00648401 Comparator | Jan 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verelan PM Extended-Release Capsules, 300 mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00648401 ↗ |
| Route | Oral | “following a single, oral 300 mg (1 x 300 mg) dose administration under fed conditions” NCT00648401 ↗ |